CN112662752B - Application of biomarker for diagnosis - Google Patents
Application of biomarker for diagnosis Download PDFInfo
- Publication number
- CN112662752B CN112662752B CN202110064427.8A CN202110064427A CN112662752B CN 112662752 B CN112662752 B CN 112662752B CN 202110064427 A CN202110064427 A CN 202110064427A CN 112662752 B CN112662752 B CN 112662752B
- Authority
- CN
- China
- Prior art keywords
- mir
- polycystic ovarian
- ovarian syndrome
- biomarker
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Abstract
The invention provides a miRNA biomarker for diagnosis of polycystic ovarian syndrome, wherein the miRNA biomarker is miR-615-5 p. The method detects the expression of miR-615-5p in parietal granulosa cells, cumulus granulosa cells and serum of PCOS patients and healthy controls, and finds that the level of miR-615-5p is remarkably reduced. Overexpression of miR-615-5p in human primary granulosa cells and human ovarian granulosa cell line KGN promotes granulosa cell proliferation and estrogen production. DHT (dihydrotestosterone) is adopted to induce a mouse polycystic ovarian syndrome mouse model, and miR-615-5p is found to be low in expression in the ovary of the mouse model of polycystic ovarian syndrome. The research shows that miR-615-5p can be used as a biomarker of polycystic ovarian syndrome and provides a theoretical basis for clinical pharmacy.
Description
Technical Field
The present invention relates to the fields of molecular biology and disease gene research and diagnosis. Specifically, the invention relates to a microRNA biomarker of polycystic ovarian syndrome (PCOS) and application of the microRNA in preparation of a kit or a gene chip for diagnosing or detecting the polycystic ovarian syndrome.
Background
Polycystic ovary syndrome (PCOS) affects 6-8% of women of reproductive age, one of the most common endocrine disorders. The most common clinical manifestations of the disease are hyperandrogenism in women, resulting in menstrual disorders, rarity, amenorrhea or irregular vaginal bleeding, infertility, obesity, hirsutism, endometrial hyperproliferation and malignant changes, and polycystic changes in bilateral or unilateral ovaries with a high incidence of the obese phenotype; insulin resistance occurs in the endocrine metabolism of glycolipid, which leads to complications such as diabetes, and long-term complications also include cardiovascular diseases, endometrial cancer and the like. The clinical manifestations of PCOS are heterogeneous, and the research on the relevant mechanisms of the disease has been a hotspot and difficulty in the basic research. Thus, a further understanding of the molecular mechanisms underlying PCOS pathophysiology may help identify new diagnostic and therapeutic targets.
miRNA is small non-coding RNA with the endogenous length of about 21-25nt, and plays an important role in regulating and controlling the degradation and inhibition of target gene mRNA. mirnas, as biomarkers of potential tissue-specific diseases, can provide effective measures for many pathological diagnoses. Abnormal expression of miRNAs is associated with several metabolic disorders (including obesity, diabetes, PCOS, etc.), and several studies have highlighted the function of miRNAs to maintain metabolic homeostasis. Thus, mirnas are potential regulators of metabolic processes and are promising targets for the regulation of PCOS and related disease-related complex pathways.
Disclosure of Invention
The present invention provides miRNA biomarkers indicative of polycystic ovarian syndrome (PCOS). The present invention provides methods for detecting or diagnosing PCOS by detecting changes in the expression levels of mirnas of the biomarkers in a sample, particularly a granulosa cell sample, and kits or gene chips for use in these methods.
The miRNA biomarker for diagnosis of polycystic ovarian syndrome provided by the invention is miR-615-5 p. The mature sequence is as follows: GGGGGUCCCCGGUGCUCGGAUC are provided.
The invention also provides application of the miR-615-5p in preparation or screening of medicines for diagnosing and treating the polycystic ovary syndrome of the human.
The invention also provides application of the miR-615-5p in preparation of a human polycystic ovary syndrome detection reagent. The detection reagent is selected from related reagents for detecting the biomarker miR-615-5p by methods such as southern blotting, northern blotting, PCR (polymerase chain reaction), reverse transcriptase PCR (polymerase chain reaction), real-time quantitative PCR (polymerase chain reaction), nano-array method, macro-array method, autoradiography or in-situ hybridization.
The invention further provides a kit for diagnosing polycystic ovarian syndrome, which comprises one or more primers and/or probes for specifically detecting the expression level of miR-615-5 p.
The primer is designed based on the real-time quantitative PCR method for detecting miR-615-5p, and the primer sequence is as follows:
miR-615-5p-RT:5’-GTCGTATCCAGTGCAGGGTCCGAGGTGCACTGGATACGACCATCCGA-3’
miR-615-5p-F:5’-TGCACGGGGGTCCCCGGTGCTCG-3’
miR-615-5p-R:5’-CTCAACTGGTGTCGTGGAGTC-3’
mirnas are widely expressed in female reproductive tract ovaries, uterus, endometrium, oviducts, and during embryonic development, and by specifically binding to their target genes, cause degradation of the target mRNA or inhibit its translation. The research on miRNA is complete and enriches the molecular biology and genetics mechanisms of disease occurrence and development. Research shows that the overexpression of miR-615-5p promotes the proliferation of granulosa cells and the generation of estrogen. The low expression of miR-615-5p in granulosa cells causes the dyssecretion of estrogen and androgen in follicular membranes of the granulosa cells, and causes polycystic ovary syndrome.
The invention detects the expression of miR-615-5p in parietal granulosa cells, cumulus granulosa cells and serum of PCOS patients and normal people, and finds that the miR-615-5p level is obviously reduced. The over-expression of miR-615-5p in the granular cells promotes the proliferation of the granular cells and the production of estrogen. DHT (dihydrotestosterone) is adopted to induce a mouse polycystic ovarian syndrome model, and miR-615-5p is found to be low in expression in the ovary of the mouse of the polycystic ovarian syndrome model. miR-615-5p can be used as a biomarker of polycystic ovarian syndrome, and provides a theoretical basis for clinical pharmacy.
Drawings
Fig. 1 is a graph of miR-615-5p expression in parietal granulosa cells from healthy controls (n-8), PCOS patients (n-15) in example 1 of the present invention;
fig. 2 is a graph of miR-615-5p expression in cumulus granular cells from healthy controls (n-16), PCOS patients (n-17) in example 1 of the present invention;
fig. 3 is the expression of miR-615-5p in sera from healthy controls (n-17), PCOS patients (n-16) in example 1 of the present invention;
FIG. 4 shows that miR-615-5p overexpression promotes the production of human primary granulosa cell (hGC) estrogen in example 2 of the present invention;
FIG. 5 shows that miR-615-5p overexpression promotes secretion of estrogen in KGN cell line in example 2 of the present invention;
FIG. 6 shows that the ovaries of offspring adult female mice in the PCOS model group of example 3 of the present invention, i.e., DHT-treated group, exhibited a polycystic shape;
FIG. 7 shows that the expression level of miR-615-5p in ovary of polycystic ovary syndrome model mouse in example 3 of the invention is remarkably reduced.
Detailed Description
The following examples are intended to illustrate the invention, but are not intended to limit the scope of the invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are commercially available.
Example 1 application of miR-615-5p as miRNA biomarker for diagnosis of polycystic ovarian syndrome
The expression of miR-615-5p in human granulosa cells was quantitatively analyzed by RNA extraction, reverse transcription and real-time (RT) -PCR.
1. Total RNA was extracted from human granulosa cells using standard extraction protocols based on TRIzol, quantitated using a NanoDrop 1000 spectrophotometer, and then stored at-80 ℃ if not used immediately, according to the manufacturer's instructions.
2. RT was performed using a complementary DNA synthesis kit (Thermo Fisher Scientific) under the following conditions: 42 ℃ for 90 minutes, 95 ℃ for 5 minutes, held at 4 ℃. Reverse transcription of miRNA is performed using a Stem-loop RT-Primer specific for miRNA as a Primer. Its internal reference is small nuclear RNAU 6. The reverse transcription primer for U6 was 5'-AACGCTTCACGAATTTGCGT-3'. The reverse primer of miR-615-5p is 5'-GTCGTATCCAGTGCAGGGTCCGAGGTGCACTGGATACGACCATCCGA-3'.
3. Complementary DNA was amplified in a Roche LightCycler 480 system using SYBR Green Master Mix Reagent (Roche, Switzerland). The cycling conditions were as follows: denaturation at 95 ℃ for 10 min, then at 95 ℃ for 10 sec, at 60 ℃ for 10 sec, and at 72 ℃ for 10 cycles of 40 cycles. The amplification primers were as follows:
U6-F:5’-CTCGCTTCGGCAGCACA-3’；
U6-R:5’-AACGCTTCACGAATTTGCGT-3’；
miR-615-5p-F:5’-TGCACGGGGGTCCCCGGTGCTCG-3’；
miR-615-5p-R:5’-CTCAACTGGTGTCGTGGAGTC-3’
the data obtained were analyzed using 480software, Version 1.5.
The analysis result shows that the expression of miR-615-5p in the parietal granulosa cells, cumulus granulosa cells and serum of the PCOS patient is remarkably increased compared with the control group (figures 1-3).
Example 2 Effect of miR-615-5p on the promotion of steroid production
Human primary granular cells (hCG) and a human ovarian granular cell line (KGN) are cultured in vitro and divided into a miR-615-5p group and a control group, miR-615-5p (namely miR-615-5p imic, GGGGGUCCCCGGUGCUCGGAUC) and miR-NC are transfected respectively, and the change of the estrogen content in cell supernatant is detected.
1. Effect of miR-615-5p on estradiol secretion by granulosa cells
(1) Cell transfection
Lipofectamine manufactured by Invitrogen corporation was used TM 2000, operating as per the instructions (taking 6-well plates, A, B in total, one well for each group, 3 multiple wells for each treatment group at the time of actual transfection):
cells were seeded 24 hours before transfection (4X 10) 5 One/well), cultured in serum-containing medium, and the cell anchorage rate is about 70-80% after 24 hours; changing a serum-free culture medium 2 hours before transfection; transfection was performed in the following A, B two panels, with panel C being the diluted transfection reagent.
A: 100pmol miR-NC mici (mimic) + 250. mu.L serum-free DMEM/F12 medium
B: 100pmol miR-615-5p micic (mimic) +250 uL serum-free DMEM/F12 medium
C：5μL Lipofectamine TM 2000+250 mu L serum-free DMEM/F12 medium
The two groups of premixed liquid are prepared, blown, beaten and uniformly mixed, and are kept stand for 5 minutes at room temperature. And (3) mixing the two groups of premixed solutions with the group C premixed solution in equal volume respectively to obtain about 500 mu L of transfection reagent (small RNA mixed solution), blowing and uniformly mixing, incubating at room temperature for 20 minutes, adding 500 mu L of the prepared transfection reagent into each hole, incubating in an incubator at 37 ℃ for 6 hours, changing to a normal 10% FBS DMEM/F12 culture medium, continuing culturing for 18-48 hours, and observing the result.
(2) Cytokine assay
The transfected cells were cultured for 48 hours, and the culture broth was collected and sent to the institute of biotechnology in northern Beijing to determine the estradiol content.
According to measurement, miR-615-5p promotes the secretion of estrogen of human primary granulosa cells and KGN cell lines (figure 4 and figure 5).
Example 3 in vivo experiment of decreased expression of miR-615-5p in the ovary of polycystic ovary syndrome model mouse: 10 female mice with a gestational period of 16 days were randomly divided into two groups.
The control group was subcutaneously injected with 200ul of sesame oil per day, and the experimental group was subcutaneously injected with 200ul of sesame oil containing DHT (dihydrotestosterone) (wherein the amount of DHT was 250ug) per day for 3 days. Collecting ovaries of offspring adult female mice, making paraffin sections, HE staining, and observing the ovary structure. And simultaneously extracting RNA of the ovary, and detecting the expression condition of miR-615-5 p.
Adult C57 female mice and male mice are combined in a ratio of 2:1 at 4 pm in the first 1 day, the emboli are picked up in the morning of the next day, and female mice with emboli are marked and divided into two groups, which is marked as day 1. The control mice were injected with 200ul of sesame oil subcutaneously into the back of each day 16, 17, and 18 days after the treatment of thrombosis, and the experimental mice were injected with 200ul of sesame oil containing DHT (dihydrotestosterone) (wherein the amount of DHT was 250ug) subcutaneously into the back of each day for 3 days. After 2 months, ovaries of offspring female mice were collected, fixed with 4% paraformaldehyde for 48 hours, washed with running water for 6 hours, embedded, HE-stained, and observed under a microscope for ovarian structure.
The results showed that the ovaries of the offspring adult female mice in the DHT-treated group exhibited a multivesicular shape compared to the control group (fig. 6).
The embedding steps are as follows:
70% ethanol 15 min-80% ethanol 15 min-90% ethanol 15 min-95% ethanol 15 min-absolute ethanol 115 min-absolute ethanol 215 min-ethanol/xylene (1:1)7 min-xylene 16 min-xylene 26 min-paraffin 118 min-paraffin 218 min-paraffin 318 min.
The absolute ethyl alcohol 1 is soaked in a first absolute ethyl alcohol plate for 15 minutes, and then taken out and placed in a second absolute ethyl alcohol plate to be soaked for 15 minutes. Xylene and paraffin are similar.
HE staining procedure was as follows:
xylene 115 min- - -xylene 215 min- - -alcohol/xylene (1:1)5min- - -absolute ethyl alcohol 15min- - -absolute ethyl alcohol 25 min- - -95% ethyl alcohol 5min- - -80% ethyl alcohol 5min- - -70% ethyl alcohol 5min- - -hematoxylin 12min- - -distilled water washing 2min- - -hydrochloric acid alcohol 10s- - -distilled water washing 2min- - -70% ethyl alcohol 3min- - -80% ethyl alcohol 3min- - -eosin 60s- - -90% ethyl alcohol 3min- - -95% ethyl alcohol 3min- - -absolute ethyl alcohol 13 min- - -absolute ethyl alcohol 23 min- - -alcohol/xylene (1:1)3min- - -xylene 13 min- - -xylene 23 min- - -xylene -a cover sheet.
Extracting total RNA of the ovary, and detecting the expression condition of miR-615-5 p.
The result shows that the expression level of miR-615-5p in the ovary of a polycystic ovary syndrome model mouse is remarkably reduced (figure 7).
Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Sequence listing
<110> university of agriculture in China
<120> use of biomarker for diagnosis
<130> MP21000735Z
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 22
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
gggggucccc ggugcucgga uc 22
<210> 2
<211> 22
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
gggggucccc ggugcucgga uc 22
<210> 3
<211> 22
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
uccgagcacc ggggaccccc uu 22
<210> 4
<211> 47
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
gtcgtatcca gtgcagggtc cgaggtgcac tggatacgac catccga 47
<210> 5
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
tgcacggggg tccccggtgc tcg 23
<210> 6
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
ctcaactggt gtcgtggagt c 21
Claims (4)
1. Application of miRNA biomarker miR-615-5p for diagnosis of polycystic ovarian syndrome in preparation of human polycystic ovarian syndrome detection reagent.
2. The use according to claim 1, wherein the detection reagent is selected from reagents related to the detection of the biomarker miR-615-5p by Southern blotting, Northern blotting, PCR, reverse transcriptase PCR, real-time quantitative PCR, nanoarray, macroarray, autoradiography or in situ hybridization.
3. The application of the miRNA biomarker miR-615-5p for diagnosing the polycystic ovarian syndrome in preparing a kit for diagnosing the polycystic ovarian syndrome is characterized in that the kit comprises a primer and a probe for specifically detecting the expression level of miR-615-5 p.
4. The kit according to claim 3, wherein the kit comprises primers for detecting miR-615-5p by a real-time quantitative PCR method, and the sequences of the primers are as follows:
miR-615-5p-RT:5′-GTCGTATCCAGTGCAGGGTCCGAGGTGCACTGG ATACGACCATCCGA-3′
miR-615-5p-F:5′-TGCACGGGGGTCCCCGGTGCTCG-3′
miR-615-5p-R:5′-CTCAACTGGTGTCGTGGAGTC-3′。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110064427.8A CN112662752B (en) | 2021-01-18 | 2021-01-18 | Application of biomarker for diagnosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110064427.8A CN112662752B (en) | 2021-01-18 | 2021-01-18 | Application of biomarker for diagnosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112662752A CN112662752A (en) | 2021-04-16 |
| CN112662752B true CN112662752B (en) | 2022-08-23 |
Family
ID=75415544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110064427.8A Active CN112662752B (en) | 2021-01-18 | 2021-01-18 | Application of biomarker for diagnosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112662752B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113186275A (en) * | 2021-06-16 | 2021-07-30 | 上海交通大学医学院附属仁济医院 | Application of serum amyloid A1 in preparation of biomarker for diagnosing polycystic ovarian syndrome |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105779589A (en) * | 2016-03-07 | 2016-07-20 | 中国农业大学 | miRNA biomarker for diagnosis of polycystic ovarian syndromes and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120219958A1 (en) * | 2009-11-09 | 2012-08-30 | Yale University | MicroRNA Signatures Differentiating Uterine and Ovarian Papillary Serous Tumors |
| EP2354246A1 (en) * | 2010-02-05 | 2011-08-10 | febit holding GmbH | miRNA in the diagnosis of ovarian cancer |
| BR112015023275B1 (en) * | 2013-03-15 | 2022-06-21 | Board Of Regents, The University Of Texas System | In vitro method of cancer biomarker detection |
-
2021
- 2021-01-18 CN CN202110064427.8A patent/CN112662752B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105779589A (en) * | 2016-03-07 | 2016-07-20 | 中国农业大学 | miRNA biomarker for diagnosis of polycystic ovarian syndromes and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| Altered microRNAs expression profiling in cumulus cells from patients with polycystic ovary syndrome;Suying Liu et al;《J Transl Med》;20151231;第13卷;参见摘要、结果以及表2 * |
| 多囊卵巢综合征患者卵巢颗粒细胞中雄激素相关microRNA的表达;徐岚等;《中国妇幼保健》;20160501(第09期);全文 * |
| 微RNA在多囊卵巢综合征发病机制中的研究进展;李忆昆等;《医学综述》;20201231(第09期);全文 * |
| 微小RNA在卵巢颗粒细胞中的研究进展;魏超峰等;《国际生殖健康/计划生育杂志》;20200715(第04期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112662752A (en) | 2021-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | The role of MiRNA in polycystic ovary syndrome (PCOS) | |
| Mu et al. | Non-coding RNAs in polycystic ovary syndrome: a systematic review and meta-analysis | |
| Roth et al. | Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome | |
| Xu et al. | Differentially expressed micoRNAs in human oocytes | |
| Bittel et al. | Whole genome microarray analysis of gene expression in Prader–Willi syndrome | |
| Luo et al. | The role of miRNAs in polycystic ovary syndrome with insulin resistance | |
| Hong et al. | Down-regulation of miR-378a-3p induces decidual cell apoptosis: a possible mechanism for early pregnancy loss | |
| Song et al. | miRNA-592 is downregulated and may target LHCGR in polycystic ovary syndrome patients | |
| CN105779589A (en) | miRNA biomarker for diagnosis of polycystic ovarian syndromes and application thereof | |
| CN107674916B (en) | Application of circular RNA in colorectal cancer biomarker | |
| CN112662752B (en) | Application of biomarker for diagnosis | |
| CN106967794B (en) | Kit and method for detecting miRNA (micro ribonucleic acid) by bidirectional signal amplification | |
| CN112852946A (en) | Diagnostic biomarker and application thereof | |
| CN112430665B (en) | Molecular biomarker for diagnosing and treating triple negative breast cancer and application thereof | |
| CN108300788B (en) | Micro ribonucleic acid composition for detecting light brain trauma and application thereof | |
| CN112342288A (en) | Application of biomarker for diagnosis | |
| Juchnicka et al. | Influence of MiRNAs in gestational diabetes mellitus development | |
| Bao et al. | MiRNA-203a-5p alleviates the malignant progression of Wilms' tumor via targeting JAG1. | |
| CN112143790B (en) | Method for assessing risk of Down syndrome based on m6A methylation modification of NRIP1 mRNA and application thereof | |
| CN112626220A (en) | Biomarker and application thereof | |
| CN102094070A (en) | mRNA in-situ hybridization kit for detecting overexpression of HER2 | |
| Neuhausser et al. | Identification of miR-34-3p as a candidate follicular phase serum marker for endometriosis: a pilot study | |
| Monfared et al. | Determination and comparison miR 5a in the serum between women with GDM, non-pregnant type diabetes, healthy pregnant and control group | |
| CN112143807A (en) | Biomarker and application thereof | |
| CN111269987B (en) | Diagnostic prognosis marker MAPK8IP1P2 for thyroid cancer and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |